GILD reports positive results for Livdelzi in PBC patients with mild ALP elevation

June 2, 2026 8:30 AM

Gilead Sciences Inc. (NASDAQ: GILD) announced that its Phase 3 IDEAL trial of Livdelzi (seladelpar) met its primary endpoint in ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found